AMAG Pharma Fails To Shirk Drug-Risks Investor Suit
A Massachusetts federal court rejected a motion to dismiss a putative class action accusing AMAG Pharmaceuticals Inc. and its bank underwriters of misleading investors about the risks of iron deficiency treatment...To view the full article, register now.
Already a subscriber? Click here to view full article